> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
> See specialized channels

  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter

Selvita Ranked the No. 1 Rising Star in Deloitte Technology Fast 50 Central Europe

| Print |
Tuesday, 18 October 2011 11:15 (UTC + 2)


Kraków, Poland, October  18, 2011 / B3C newswire / - Selvita S.A. has been ranked as the no.1 Rising Star within this year’s contest of Deloitte Technology Fast 50 in Central Europe.

The Central Europe Technology Fast 50 program, is part of a global effort by Deloitte to identify the fastest growing technology companies all over the world, which became a recognized benchmark of success in the technology industry. This prestigious annual award honors the fastest growing Central European technology companies, based on the percentage of revenue growth over certain period of time.

In this year’s edition, Selvita was voted as the no. 1 Rising Star, meaning a young, emerging company with the most potential to grow. With the result of a 2 623% increase in revenues over the past three years, Selvita beat a long list of high technology companies from Albania, Bosnia & Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Macedonia, Moldova, Poland, Romania, Serbia, Montenegro, Slovakia and Slovenia.

What’s more, Selvita is also the only biotechnology company which can be found in the ranking.

Pawel Przewiezlikowski, Selvita’s CEO, received the no 1 Rising Star award, during the official XII Deloitte Technology Fast 50 Central Europe, on 17th October 2011, in Warsaw, naming Selvita the most promising and fastest developing emerging company in Central Europe.

Read more: www.deloitte.com and www.selvita.com

About Selvita
Selvita Group is an independent integrated drug discovery provider.  Selvita offers its clients services ranging from computational chemistry, through chemical development to preclinical in vitro research, done in-house. Company’s mission is to serve its clients with a comprehensive panel of products and solutions targeted at lowering the cost of, and accelerating the introduction of new drugs to the market. Since 2010, Selvita is the owner of BioCentrum, which provides in vitro preclinical ADMET services, analytical services and  biochemistry services with special focus on protein engineering and antibody development. Selvita' Group laboratories are certified with the Good Laboratory Practice (GLP) certificate, as well as have the accreditation of Polish General Pharmaceutical Inspectorate.

Media contact
Natalia Pawela
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
+48 12 297 47 31